The aim of this study was to estimate the prevalence of IgG and IgM antibodies against B19V, and to detect B19 DNA, in patients with hematological diseases undergoing METHODS: Plasma samples from 421 patients were subjected to enzyme immunoassay for the detection of anti-B19V IgG and IgM antibodies. This evidence concerns the gene CD40LG and hematologic disorder.